Oligodendrocytes can regenerate, but the process is limited and becomes less efficient with age and disease. Your brain maintains a built-in repair system: a population of stem-like cells called oligodendrocyte progenitor cells (OPCs) that account for roughly 5% of all cells in the adult brain. These progenitor cells can divide, migrate to damaged areas, and mature into new oligodendrocytes capable of producing myelin, the insulating coating around nerve fibers. The catch is that this regeneration often stalls partway through, especially in chronic conditions like multiple sclerosis.
How the Brain Rebuilds Myelin
When oligodendrocytes die or myelin is damaged, nearby OPCs respond quickly. They begin proliferating almost immediately after injury and can start maturing into new oligodendrocytes within as little as three days. However, the full process of wrapping axons with detectable compact myelin takes longer, typically around two weeks or more after injury. In chemically induced demyelination in animal models, OPCs surrounding the damaged area proliferate, migrate into the lesion, and differentiate into remyelinating oligodendrocytes within about three weeks.
The maturation process follows a tightly controlled sequence. OPCs must first express two key proteins simultaneously before differentiation can begin. Once that threshold is met, a master regulatory protein called MYRF drives the transition from an immature state to a fully functional, myelin-producing cell. MYRF has to physically split itself apart and reassemble in a new form before it can enter the cell nucleus and switch on the genes responsible for building myelin. This multi-step activation acts as a quality control checkpoint, ensuring cells don’t start producing myelin prematurely.
Why Regeneration Slows With Age
OPCs in younger brains are highly excitable and responsive to signals from nearby neurons. Nerve activity acts as a key trigger telling OPCs when and where to start making myelin. As people age, OPCs lose the receptors that make them sensitive to these neuronal signals. Their electrical excitability drops, and with it, their ability to respond to cues that would normally prompt them to mature and myelinate.
These changes happen at different rates in different brain regions. In areas that don’t produce much myelin to begin with, the receptors disappear early. In regions involved in generating new neurons, they persist throughout life. The surrounding environment matters too. Animal studies show that exposing aged OPCs to signals from young neurons can partially restore their responsiveness, suggesting the decline isn’t entirely hardwired into the cells themselves but is also driven by changes in the brain’s chemical environment over time.
What Blocks Repair in Multiple Sclerosis
In MS, the immune system attacks myelin, creating lesions throughout the brain and spinal cord. The brain does attempt to repair these lesions, and remyelination is more successful in early stages of the disease than in later ones. OPCs are present in both active and chronic MS plaques, meaning the raw material for repair is often there. The problem is that these cells frequently fail to mature into functioning oligodendrocytes.
Several factors contribute to this failure. In chronic MS lesions, chemical modifications to DNA-packaging proteins (histones) shift toward a pattern that actively blocks OPC maturation. Early lesions don’t show this pattern, which helps explain why repair works better early on. The scar tissue that forms at injury sites also creates both a physical and chemical barrier. OPCs within scar tissue produce molecules called chondroitin sulfate proteoglycans that inhibit nerve fiber regrowth, essentially creating a hostile environment for the very repair process they’re supposed to support.
A damaging feedback loop can also develop. As oligodendrocytes become dysfunctional, they stop producing growth factors that OPCs need to proliferate and mature. Fewer growth factors mean fewer new oligodendrocytes, which means even less growth factor production. This vicious cycle becomes more pronounced in the later stages of the disease and may account for much of the progressive disability seen in advanced MS.
Gray Matter vs. White Matter
Not all brain regions regenerate myelin equally well. Oligodendrocytes from gray matter (the outer layer of the brain rich in cell bodies) show a greater intrinsic capacity to myelinate compared to those from white matter (the deeper tracts of nerve fibers). A higher percentage of gray matter oligodendrocyte lineage cells actively wrap around axons when given the opportunity. However, gray matter oligodendrocytes are also more vulnerable to metabolic injury, meaning they’re more easily killed off in the first place. This trade-off, greater repair potential but greater fragility, reflects the fact that gray matter oligodendrocytes tend to be at an earlier, more flexible stage of development.
Exercise and Oligodendrocyte Health
Aerobic exercise appears to support oligodendrocyte regeneration, at least in animal models. In rats subjected to chronic stress (which damages oligodendrocytes in the prefrontal cortex), six weeks of running exercise significantly increased the number of mature oligodendrocytes and boosted production of myelin-related proteins. The exercise didn’t simply increase the number of progenitor cells. Instead, it promoted the differentiation of existing progenitors into mature, myelin-producing oligodendrocytes. Running also reversed the brain volume loss caused by chronic stress in these animals, suggesting the myelin recovery had meaningful structural effects.
Drugs Being Tested for Remyelination
The most studied remyelination drug to date is clemastine, an over-the-counter antihistamine that also blocks a receptor involved in keeping OPCs in an immature state. In the ReBUILD trial, a double-blind, placebo-controlled study in people with relapsing MS, clemastine improved the speed of visual nerve signaling, a marker that reflects myelin integrity. MRI analysis from the same trial showed increased myelin content in the corpus callosum, the large white matter tract connecting the brain’s hemispheres. Sedation was a notable side effect.
A newer compound called PIPE-307 targets the same receptor as clemastine but is designed to be more selective, potentially avoiding the drowsiness. It has completed Phase I trials in healthy volunteers and is currently in Phase II testing in people with MS.
How Remyelination Is Measured
Proving that oligodendrocyte regeneration is actually happening inside a living person requires specialized imaging. The most commonly used approach is magnetization transfer ratio on MRI, which is sensitive to myelin but can be influenced by other tissue properties, limiting its specificity. A more precise technique uses a sequence called MP2RAGE, which maps a property of tissue called T1 relaxation time. At ultra-high-field 7-Tesla MRI, this method can distinguish remyelinated lesions from those that remain demyelinated. When combined with imaging that detects iron deposits at lesion edges (a sign of ongoing inflammation), researchers can classify most chronic MS lesions into active, inactive, or remyelinated categories. This approach is increasingly being used to track participants in clinical trials testing remyelination therapies.